생체 접착제 시장 - 규모, 점유율, 성장률, 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of bioconjugation Market

The global bioconjugation market size was valued at USD 4.78 billion in 2025 and is projected to grow from USD 5.24 billion in 2026 to USD 11.39 billion by 2034, registering a CAGR of 10.20% during the forecast period. North America dominated the bioconjugation market with a market share of 51.82% in 2025, supported by strong biopharmaceutical R&D activities and advanced manufacturing capabilities.

Bioconjugation refers to the chemical linking of two distinct molecules, typically through covalent bonding, to create a functional complex. This technology is widely used in the development of antibody-drug conjugates (ADCs), diagnostics, molecular imaging agents, and targeted therapeutics. Rising demand for targeted therapies, increasing R&D investments, and continuous technological advancements are accelerating the adoption of bioconjugation across therapeutic and diagnostic applications. Additionally, increasing collaborations between biopharmaceutical companies and contract research and manufacturing organizations (CROs/CDMOs) are further supporting market growth.

Major players such as Thermo Fisher Scientific Inc., Agilent Technologies Inc., and Lonza dominate the market owing to their broad service offerings, global presence, and strong technological capabilities.

MARKET DYNAMICS

MARKET DRIVERS

Increasing Focus on Antibody-Drug Conjugates (ADCs)

The growing emphasis on the development of antibody-drug conjugates is a key driver of the bioconjugation market. ADCs combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs, enabling targeted cancer treatment with reduced systemic toxicity. Advancements in site-specific conjugation technologies have improved drug stability, efficacy, and safety profiles, leading to an expanding pipeline of ADCs.

According to data published by Hunan Huateng Pharmaceutical Co., Ltd. in April 2025, a total of 19 ADC drugs have been approved globally to date.

MARKET RESTRAINTS

Regulatory and Safety Challenges

Stringent regulatory requirements and safety concerns pose significant restraints on market growth. Novel bioconjugates face complex regulatory pathways due to risks such as off-target toxicity and premature drug release. These factors result in longer approval timelines and increased development costs, potentially delaying commercialization.

For instance, in July 2023, ADC Therapeutics SA discontinued the Phase II LOTIS-9 trial due to safety and efficacy concerns.

MARKET OPPORTUNITIES

Growing Demand for Companion Diagnostics and Imaging Agents

Bioconjugation plays a crucial role in precision diagnostics and molecular imaging by enabling the attachment of imaging probes, radioactive isotopes, and fluorescent dyes to antibodies or peptides. The increasing adoption of companion diagnostics and imaging agents, particularly in oncology, presents significant growth opportunities for the market.

MARKET CHALLENGES

High Cost and Technical Complexity

The development of bioconjugated therapeutics, especially ADCs, involves complex manufacturing processes, sophisticated equipment, and extensive clinical trials. According to a June 2023 NCBI study, the annual cost of ADC therapy ranges between USD 100,000 and USD 500,000, which limits accessibility and adoption.

BIOCONJUGATION MARKET TRENDS

Rising Outsourcing to CROs and CDMOs

Pharmaceutical and biotechnology companies are increasingly outsourcing conjugation and characterization activities to specialized CROs and CDMOs. This trend allows companies to reduce capital expenditure, access advanced technologies, and accelerate development timelines. In October 2024, Lonza expanded its collaboration with a major biopharmaceutical company for commercial-scale ADC manufacturing.

SEGMENTATION ANALYSIS

By Offering:

The products segment dominated the market with a 75.83% share in 2026, driven by high demand for consumables used in drug development, diagnostics, and research.

By Technique:

The chemical conjugation segment held the largest share at 47.68% in 2026, owing to its cost-effectiveness and wide applicability.

By Conjugate Type:

Antibody-drug conjugates (ADCs) accounted for 56.91% of the market in 2026, supported by strong oncology pipelines.

By Application:

The therapeutics segment dominated with 66.0% share in 2025 and 66.74% in 2026, driven by increasing approvals of targeted therapies.

By End User:

Pharmaceutical & biotechnology companies held 56.7% share in 2025, supported by strong focus on innovative therapeutic development.

REGIONAL OUTLOOK

North America led the market with USD 2.48 billion in 2025 and USD 2.72 billion in 2026, driven by strong R&D investments and a robust CRO/CDMO ecosystem.

Europe reached USD 1.23 billion in 2025, growing at a CAGR of 9.82%.

Asia Pacific attained USD 0.84 billion in 2026, with China and India each reaching USD 0.15-0.16 billion.

Latin America recorded USD 0.419 billion in 2025, while Middle East & Africa (GCC) reached USD 0.06 billion.

COMPETITIVE LANDSCAPE

The bioconjugation market is semi-consolidated, with leading players such as Thermo Fisher Scientific Inc., Merck KGaA, Lonza, Danaher, and Catalent, Inc. focusing on expanding conjugation capabilities, ADC pipelines, and service offerings. Strategic investments and collaborations continue to strengthen competitive positioning.

Conclusion

The global bioconjugation market is positioned for strong growth, driven by rising demand for targeted therapeutics, expanding ADC pipelines, and increasing outsourcing to specialized CROs and CDMOs. With the market valued at USD 4.78 billion in 2025, expected to reach USD 5.24 billion in 2026 and USD 11.39 billion by 2034, sustained innovation and strategic collaborations will remain key growth enablers. Despite regulatory and cost-related challenges, advancements in conjugation technologies and growing applications in diagnostics and therapeutics are expected to support consistent market expansion over the forecast period.

Segmentation By Offering, Technique, Conjugate Type, Application, End User, and Region

By Offering * Products

• Instruments
  • Chromatography Systems
  • Spectroscopy Instruments
  • Mass Spectrometers
  • Flow Cytometers
  • Others
• Consumables
  • Reagents & Kits
  • Labels
  • Others
• Services
  • Custom Synthesis & Conjugation Services
  • Analytical & Characterization Services
  • Scale-up & Manufacturing Services
  • Others

By Technique * Chemical Conjugation

• Enzyme-Mediated Conjugation
• Click Chemistry
• Photoreactive Crosslinking
• Others

By Conjugate Type * Antibody-Drug Conjugates (ADCs)

• Protein-Drug Conjugates
• Peptide-Drug Conjugates
• Others

By Application * Therapeutics

• Diagnostics
• Research & Development

By End User * Pharmaceutical & Biotechnology Companies

• CROs & CDMOs
• Academic & Research Institutes
• Others

By Region * North America (By Offering, Technique, Conjugate Type, Application, End User, and Country)

• U.S.
• Canada
• Europe (By Offering, Technique, Conjugate Type, Application, End User, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Offering, Technique, Conjugate Type, Application, End User, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Offering, Technique, Conjugate Type, Application, End User, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Offering, Technique, Conjugate Type, Application, End User, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Technological Advancements in Bioconjugation
• 4.2. Regulatory Scenario, By Key Countries/Regions
• 4.3. Key Industry Developments (Mergers, Acquisitions, and Collaborations etc.)
• 4.4. New Product Launches, By Key Players
• 4.5. Overview: Expanding Applications of Bioconjugation

5. Global Bioconjugation Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Offering
  • 5.1.1. Products
    • 5.1.1.1. Instruments
      • 5.1.1.1.1. Chromatography Systems
      • 5.1.1.1.2. Spectroscopy Instruments
      • 5.1.1.1.3. Mass Spectrometers
      • 5.1.1.1.4. Flow Cytometers
      • 5.1.1.1.5. Others
    • 5.1.1.2. Consumables
      • 5.1.1.2.1. Reagents & Kits
      • 5.1.1.2.2. Labels
      • 5.1.1.2.3. Others
  • 5.1.2. Services
    • 5.1.2.1. Custom Synthesis & Conjugation Services
    • 5.1.2.2. Analytical & Characterization Services
    • 5.1.2.3. Scale-up & Manufacturing Services
    • 5.1.2.4. Others
• 5.2. Market Analysis, Insights and Forecast - By Technique
  • 5.2.1. Chemical Conjugation
  • 5.2.2. Enzyme-Mediated Conjugation
  • 5.2.3. Click Chemistry
  • 5.2.4. Photoreactive Crosslinking
  • 5.2.5. Others
• 5.3. Market Analysis, Insights and Forecast - By Conjugate Type
  • 5.3.1. Antibody-Drug Conjugates (ADCs)
  • 5.3.2. Protein-Drug Conjugates
  • 5.3.3. Peptide-Drug Conjugates
  • 5.3.4. Others
• 5.4. Market Analysis, Insights and Forecast - By Application
  • 5.4.1. Therapeutics
  • 5.4.2. Diagnostics
  • 5.4.3. Research & Development
• 5.5. Market Analysis, Insights and Forecast - By End User
  • 5.5.1. Pharmaceutical & Biotechnology Companies
  • 5.5.2. CROs & CDMOs
  • 5.5.3. Academic & Research Institutes
  • 5.5.4. Others
• 5.6. Market Analysis, Insights and Forecast - By Region
  • 5.6.1. North America
  • 5.6.2. Europe
  • 5.6.3. Asia Pacific
  • 5.6.4. Latin America
  • 5.6.5. Middle East & Africa

6. North America Bioconjugation Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Offering
  • 6.1.1. Products
    • 6.1.1.1. Instruments
      • 6.1.1.1.1. Chromatography Systems
      • 6.1.1.1.2. Spectroscopy Instruments
      • 6.1.1.1.3. Mass Spectrometers
      • 6.1.1.1.4. Flow Cytometers
      • 6.1.1.1.5. Others
    • 6.1.1.2. Consumables
      • 6.1.1.2.1. Reagents & Kits
      • 6.1.1.2.2. Labels
      • 6.1.1.2.3. Others
  • 6.1.2. Services
    • 6.1.2.1. Custom Synthesis & Conjugation Services
    • 6.1.2.2. Analytical & Characterization Services
    • 6.1.2.3. Scale-up & Manufacturing Services
    • 6.1.2.4. Others
• 6.2. Market Analysis, Insights and Forecast - By Technique
  • 6.2.1. Chemical Conjugation
  • 6.2.2. Enzyme-Mediated Conjugation
  • 6.2.3. Click Chemistry
  • 6.2.4. Photoreactive Crosslinking
  • 6.2.5. Others
• 6.3. Market Analysis, Insights and Forecast - By Conjugate Type
  • 6.3.1. Antibody-Drug Conjugates (ADCs)
  • 6.3.2. Protein-Drug Conjugates
  • 6.3.3. Peptide-Drug Conjugates
  • 6.3.4. Others
• 6.4. Market Analysis, Insights and Forecast - By Application
  • 6.4.1. Therapeutics
  • 6.4.2. Diagnostics
  • 6.4.3. Research & Development
• 6.5. Market Analysis, Insights and Forecast - By End User
  • 6.5.1. Pharmaceutical & Biotechnology Companies
  • 6.5.2. CROs & CDMOs
  • 6.5.3. Academic & Research Institutes
  • 6.5.4. Others
• 6.6. Market Analysis, Insights and Forecast - By Country
  • 6.6.1. U.S.
  • 6.6.2. Canada

7. Europe Bioconjugation Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Offering
  • 7.1.1. Products
    • 7.1.1.1. Instruments
      • 7.1.1.1.1. Chromatography Systems
      • 7.1.1.1.2. Spectroscopy Instruments
      • 7.1.1.1.3. Mass Spectrometers
      • 7.1.1.1.4. Flow Cytometers
      • 7.1.1.1.5. Others
    • 7.1.1.2. Consumables
      • 7.1.1.2.1. Reagents & Kits
      • 7.1.1.2.2. Labels
      • 7.1.1.2.3. Others
  • 7.1.2. Services
    • 7.1.2.1. Custom Synthesis & Conjugation Services
    • 7.1.2.2. Analytical & Characterization Services
    • 7.1.2.3. Scale-up & Manufacturing Services
    • 7.1.2.4. Others
• 7.2. Market Analysis, Insights and Forecast - By Technique
  • 7.2.1. Chemical Conjugation
  • 7.2.2. Enzyme-Mediated Conjugation
  • 7.2.3. Click Chemistry
  • 7.2.4. Photoreactive Crosslinking
  • 7.2.5. Others
• 7.3. Market Analysis, Insights and Forecast - By Conjugate Type
  • 7.3.1. Antibody-Drug Conjugates (ADCs)
  • 7.3.2. Protein-Drug Conjugates
  • 7.3.3. Peptide-Drug Conjugates
  • 7.3.4. Others
• 7.4. Market Analysis, Insights and Forecast - By Application
  • 7.4.1. Therapeutics
  • 7.4.2. Diagnostics
  • 7.4.3. Research & Development
• 7.5. Market Analysis, Insights and Forecast - By End User
  • 7.5.1. Pharmaceutical & Biotechnology Companies
  • 7.5.2. CROs & CDMOs
  • 7.5.3. Academic & Research Institutes
  • 7.5.4. Others
• 7.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.6.1. U.K.
  • 7.6.2. Germany
  • 7.6.3. France
  • 7.6.4. Spain
  • 7.6.5. Italy
  • 7.6.6. Scandinavia
  • 7.6.7. Rest of Europe

8. Asia Pacific Bioconjugation Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Offering
  • 8.1.1. Products
    • 8.1.1.1. Instruments
      • 8.1.1.1.1. Chromatography Systems
      • 8.1.1.1.2. Spectroscopy Instruments
      • 8.1.1.1.3. Mass Spectrometers
      • 8.1.1.1.4. Flow Cytometers
      • 8.1.1.1.5. Others
    • 8.1.1.2. Consumables
      • 8.1.1.2.1. Reagents & Kits
      • 8.1.1.2.2. Labels
      • 8.1.1.2.3. Others
  • 8.1.2. Services
    • 8.1.2.1. Custom Synthesis & Conjugation Services
    • 8.1.2.2. Analytical & Characterization Services
    • 8.1.2.3. Scale-up & Manufacturing Services
    • 8.1.2.4. Others
• 8.2. Market Analysis, Insights and Forecast - By Technique
  • 8.2.1. Chemical Conjugation
  • 8.2.2. Enzyme-Mediated Conjugation
  • 8.2.3. Click Chemistry
  • 8.2.4. Photoreactive Crosslinking
  • 8.2.5. Others
• 8.3. Market Analysis, Insights and Forecast - By Conjugate Type
  • 8.3.1. Antibody-Drug Conjugates (ADCs)
  • 8.3.2. Protein-Drug Conjugates
  • 8.3.3. Peptide-Drug Conjugates
  • 8.3.4. Others
• 8.4. Market Analysis, Insights and Forecast - By Application
  • 8.4.1. Therapeutics
  • 8.4.2. Diagnostics
  • 8.4.3. Research & Development
• 8.5. Market Analysis, Insights and Forecast - By End User
  • 8.5.1. Pharmaceutical & Biotechnology Companies
  • 8.5.2. CROs & CDMOs
  • 8.5.3. Academic & Research Institutes
  • 8.5.4. Others
• 8.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.6.1. Japan
  • 8.6.2. China
  • 8.6.3. India
  • 8.6.4. Australia
  • 8.6.5. Southeast Asia
  • 8.6.6. Rest of Asia Pacific

9. Latin America Bioconjugation Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Offering
  • 9.1.1. Products
    • 9.1.1.1. Instruments
      • 9.1.1.1.1. Chromatography Systems
      • 9.1.1.1.2. Spectroscopy Instruments
      • 9.1.1.1.3. Mass Spectrometers
      • 9.1.1.1.4. Flow Cytometers
      • 9.1.1.1.5. Others
    • 9.1.1.2. Consumables
      • 9.1.1.2.1. Reagents & Kits
      • 9.1.1.2.2. Labels
      • 9.1.1.2.3. Others
  • 9.1.2. Services
    • 9.1.2.1. Custom Synthesis & Conjugation Services
    • 9.1.2.2. Analytical & Characterization Services
    • 9.1.2.3. Scale-up & Manufacturing Services
    • 9.1.2.4. Others
• 9.2. Market Analysis, Insights and Forecast - By Technique
  • 9.2.1. Chemical Conjugation
  • 9.2.2. Enzyme-Mediated Conjugation
  • 9.2.3. Click Chemistry
  • 9.2.4. Photoreactive Crosslinking
  • 9.2.5. Others
• 9.3. Market Analysis, Insights and Forecast - By Conjugate Type
  • 9.3.1. Antibody-Drug Conjugates (ADCs)
  • 9.3.2. Protein-Drug Conjugates
  • 9.3.3. Peptide-Drug Conjugates
  • 9.3.4. Others
• 9.4. Market Analysis, Insights and Forecast - By Application
  • 9.4.1. Therapeutics
  • 9.4.2. Diagnostics
  • 9.4.3. Research & Development
• 9.5. Market Analysis, Insights and Forecast - By End User
  • 9.5.1. Pharmaceutical & Biotechnology Companies
  • 9.5.2. CROs & CDMOs
  • 9.5.3. Academic & Research Institutes
  • 9.5.4. Others
• 9.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.6.1. Brazil
  • 9.6.2. Mexico
  • 9.6.3. Rest of Latin America

10. Middle East & Africa Bioconjugation Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Offering
  • 10.1.1. Products
    • 10.1.1.1. Instruments
      • 10.1.1.1.1. Chromatography Systems
      • 10.1.1.1.2. Spectroscopy Instruments
      • 10.1.1.1.3. Mass Spectrometers
      • 10.1.1.1.4. Flow Cytometers
      • 10.1.1.1.5. Others
    • 10.1.1.2. Consumables
      • 10.1.1.2.1. Reagents & Kits
      • 10.1.1.2.2. Labels
      • 10.1.1.2.3. Others
  • 10.1.2. Services
    • 10.1.2.1. Custom Synthesis & Conjugation Services
    • 10.1.2.2. Analytical & Characterization Services
    • 10.1.2.3. Scale-up & Manufacturing Services
    • 10.1.2.4. Others
• 10.2. Market Analysis, Insights and Forecast - By Technique
  • 10.2.1. Chemical Conjugation
  • 10.2.2. Enzyme-Mediated Conjugation
  • 10.2.3. Click Chemistry
  • 10.2.4. Photoreactive Crosslinking
  • 10.2.5. Others
• 10.3. Market Analysis, Insights and Forecast - By Conjugate Type
  • 10.3.1. Antibody-Drug Conjugates (ADCs)
  • 10.3.2. Protein-Drug Conjugates
  • 10.3.3. Peptide-Drug Conjugates
  • 10.3.4. Others
• 10.4. Market Analysis, Insights and Forecast - By Application
  • 10.4.1. Therapeutics
  • 10.4.2. Diagnostics
  • 10.4.3. Research & Development
• 10.5. Market Analysis, Insights and Forecast - By End User
  • 10.5.1. Pharmaceutical & Biotechnology Companies
  • 10.5.2. CROs & CDMOs
  • 10.5.3. Academic & Research Institutes
  • 10.5.4. Others
• 10.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.6.1. GCC
  • 10.6.2. South Africa
  • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles (Overview, Products & Services, SWOT analysis, Recent developments, strategies, financials (based on availability))
  • 11.2.1. Agilent Technologies Inc.
  • 11.2.2. Thermo Fisher Scientific Inc.
  • 11.2.3. Bio Rad Laboratories Inc.
  • 11.2.4. Merck KGaA
  • 11.2.5. Lonza
  • 11.2.6. Catalent, Inc.
  • 11.2.7. BD
  • 11.2.8. Sartorius AG
  • 11.2.9. Danaher
  • 11.2.10. Vector Laboratories, Inc.